Effects of DMSO, glycerol, betaine and their combinations in detecting single nucleotide polymorphisms of epidermal growth factor receptor (EGFR) gene promoter sequence in non-small-cell lung cancer (NSCLC) patients

2016 ◽  
Vol 128 ◽  
pp. 275-279 ◽  
Author(s):  
Vladimir Jurišić ◽  
Jasmina Obradović ◽  
Natasa Tošić ◽  
Sonja Pavlović ◽  
Milan Kulić ◽  
...  
Keyword(s):  
Growth Factor Receptor ◽  
Gene Promoter ◽  
Promoter Sequence ◽  
Small Cell ◽  
Nucleotide Polymorphisms ◽  
Small Cell Lung ◽  
Single Nucleotide ◽  
Egfr Gene ◽  
Epidermal Growth ◽  
Nsclc Patients

scholarly journals Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients

2021 ◽  
Vol 29 (1) ◽  
pp. 77-93
Author(s):  
Lanlan Liu ◽  
Xianzhi Xiong
Keyword(s):  
Lung Cancer ◽  
Gene Mutation ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
Egfr Gene ◽  
Epidermal Growth ◽  
Nsclc Patients ◽  
Egfr Gene Mutation

Lung cancer ranks first in the incidence and mortality of cancer in the world, of which more than 80% are non-small cell lung cancer (NSCLC). The majority of NSCLC patients are in stage IIIB~IV when they are admitted to hospital and have no opportunity for surgery. Compared with traditional chemotherapy, specific targeted therapy has a higher selectivity and fewer adverse reactions, providing a new treatment direction for advanced NSCLC patients. Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs) are the widely used targeted therapy for NSCLC patients. Their efficacy and prognosis are closely related to the mutation status of the EGFR gene. Clinically, detecting EGFR gene mutation is often limited by difficulty obtaining tissue specimens, limited detecting technology, and economic conditions, so it is of great clinical significance to find indicators to predict EGFR gene mutation status. Clinicopathological characteristics, tumor markers, liquid biopsy, and other predictors are less invasive, economical, and easier to obtain. They can be monitored in real-time, which is supposed to predict EGFR mutation status and provide guidance for the accurate, individualized diagnosis and therapy of NSCLC patients. This article reviewed the correlation between the clinical indicators and EGFR gene mutation status in NSCLC patients.

Sign in / Sign up

Export Citation Format

Share Document